Progression of White Matter Lesion Volume and Health-Related Quality of Life in Patients with Symptomatic Atherosclerotic Disease: The SMART-MR Study
Table 2
Baseline characteristics.
Total sample ()
Peripheral arterial disease ()‡
Coronary artery disease ()‡
Cerebrovascular disease ()‡
Abdominal aortic aneurysm ()‡
Age¥ (years)
58 ± 9.3
56 ± 10.2
58 ± 9.0
59 ± 9.9
62 ± 7.9
Male gender (%)
80
66
86
76
96
Smoking† (pack/years)
21 (0–53)
26 (1–56)
18 (0–51)
22 (0–53)
32 (7–76)
Alcohol use
(i) Never
13
16
12
15
8
(ii) Former
7
10
8
4
4
(iii) Current
79
74
80
82
89
Hypertension (%)
50
58
47
61
54
Diabetes mellitus (%)
16
17
16
18
27
Total intracranial volume¥ (mL)
1467 ± 127
1437 ± 132
1474 ± 123
1467 ± 128
1507 ± 125
Absolute total WML volume† (mL)
1.3 (0.4–5.8)
1.4 (0.5–4.6)
1.3 (0.3–4.7)
2.2 (0.4–11.2)
1.8 (0.5–10.3)
Physical functioning†
44 (29–55)
40 (20–53)
44 (31–55)
46 (31–56)
43 (32–55)
Mental functioning†
51 (32–60)
50 (33–60)
51 (31–60)
51 (34–59)
52 (34–58)
WML: white matter lesions. ‡The different groups of symptomatic atherosclerotic disease do not add up to the total study sample of 486, because various locations of symptomatic atherosclerotic disease can occur within one patient. ¥ Mean ± SD † Median, (10th–90th percentile).
